Life-saving treatments
for patients with
advanced liver disease
Our company
We discover and develop life-saving treatments for patients with advanced liver disease at high risk of hospitalisation and death.
Our treatments are designed either to prevent or treat rare or life-threatening liver diseases.
We have a diverse late-stage pipeline including two medical devices and two therapeutic medicines for acute and chronic use.
Yaqrit is structured with four subsidiary companies to enable investment at the asset level or the parent company level. Please be in touch if you are interested to learn more.
Latest news
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
• Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 treatment for hepatic encephalopathy
• Ex-J&J senior medtech director Sarah van Hellenberg Hubar-Fisher joins as VP Business Development leading commercial development of Yaqrit’s medical device assets
February 21, 2025
Yaqrit prepares phase 3 for ammonia scavenger in hepatic encephalopathy
• Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations
February 11, 2025
Yaqrit appoints new CEO Troels Jordansen to implement late clinical development and commercial strategy
• Successful fund raising and business development track record
London, UK: January 10, 2025
CARBALIVE beads help restore healthy gut microbiome and reduce liver disease progression
April 15, 2024
DIALIVE Liver Dialysis Device Shows Promise in First Clinical Trial for ACLF
June 1, 2023
Contact us
Troels Jordansen, Chief Executive Officer
Troels@Yaqrit.com
+31 6 1834 5326
Registered address: 34 High Street, Aldridge, Walsall, WS9 8LZ
We thank our partners at Barrington James for their support in building our world-class team.
